Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/7784
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Naci, H | - |
dc.contributor.author | Cylus, J | - |
dc.contributor.author | Vandoros, S | - |
dc.contributor.author | Sato, A | - |
dc.contributor.author | Perampaladas, K | - |
dc.date.accessioned | 2013-12-10T11:58:44Z | - |
dc.date.available | 2013-12-10T11:58:44Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | BMJ, 345, e4261, 2012 | en_US |
dc.identifier.issn | 0959-8138 | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/22872693 | en |
dc.identifier.uri | http://bura.brunel.ac.uk/handle/2438/7784 | - |
dc.description | © BMJ Publishing Group Ltd 2012 | en_US |
dc.language | eng | - |
dc.language.iso | en | en_US |
dc.publisher | BMJ Publishing Group | en_US |
dc.subject | Drug approval | en_US |
dc.subject | Drug discovery | en_US |
dc.subject | Drug industry | en_US |
dc.subject | Europe | en_US |
dc.subject | Evidence-based medicine | en_US |
dc.subject | Drug legislation | en_US |
dc.subject | Marketing of health services | en_US |
dc.subject | Treatment outcome | en_US |
dc.subject | United States | en_US |
dc.subject | United States Food and Drug Administration | en_US |
dc.title | Raising the bar for market authorisation of new drugs | en_US |
dc.type | Article | en_US |
dc.identifier.doi | http://dx.doi.org/10.1136/bmj.e4261 | - |
pubs.organisational-data | /Brunel | - |
pubs.organisational-data | /Brunel/Brunel Active Staff | - |
pubs.organisational-data | /Brunel/Brunel Active Staff/School of Social Sciences | - |
Appears in Collections: | Economics and Finance Community Health and Public Health Dept of Economics and Finance Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fulltext.pdf | 232.23 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.